NIH Launches Multi-Organizational Partnership to Advance Parkinson's Disease Clinical Trials

Edward Kim | |

To identify and validate promising biomarkers for Parkinson's disease (Image: NIH)

​Top Picks 2018: Does Glaxo SmithKline Deserve Investors' Patience?

MoneyShow | |

Glaxo is hugging the bottom of its recent trading range.

GlaxoSmithKline Gets FDA Approval for First Targeted EGPA Treatment

Edward Kim | |

First available targeted treatment for eosinophilic granulomatosis with polyangiitis (Image: ProProfs)

​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News

Mark Collins | |

Here's what just happened with Novartis and why it's so important.

​Markets May Have Got the Latest Ionis Pharmaceuticals, GlaxoSmithKline News Wrong

Mark Collins | |

Here's why the recent decision by GSK to turn down Ionis' TTR drug may not be as bad as it seems.

​Here's Where And Why VBI Vaccines Fits Into the Hepatitis B Picture

Samuel Rae | |

The company was just added to the Russell 2000 and Russell 3000 indexes.

​Why Glaxo Has Been Climbing Since the Election

MoneyShow | |

GSK broke above $42 last month after releasing strong first quarter financial results.

Three Companies Spearheading a Shift in the Hepatitis B Healthcare Space

Samuel Rae | |

A look at the frontrunners in one of the fastest growing spaces in healthcare.

Bill O'Reilly Is Losing Advertisers, but Is He Losing Fans?

CommPRO Global, Inc. | |

Tough times for Papa Bear...

​VBI Vaccines, Inc. (VBIV) is One of the Most Interesting Companies in Biotech Right Now

Samuel Rae | |

VBI Vaccines, Inc. could be a major disruptor in biotech.

Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure


Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more